- Cellestis is a developer of medical diagnostic technology with initial products to diagnose latent TB. An M-Group affiliate was a key partner in the establishment of Cellestis in 2000, has provided capital and managed the company’s IPO on the ASX. Since inception, Cellestis’s “Quantiferon-Tb” product range has become the global standard for diagnosing latent TB. The company’s IPO on the ASX was the most successful by share market return in its year of listing. Cellestis was acquired by Qiagen Inc. in a public takeover in 2011. -
Investors 1
| Date | Name | Website |
| - | Mooroolbar... | m-group.co... |